-
The fifty-seventh batch of reference preparations for chemical generic drugs (draft for comments) was released
Time of Update: 2022-04-16
25, 2019) issued by the National Bureau on March 28, 2019, the center organized the selection of The fifty-seventh batch of reference preparations is now publicized for comments .
docx 2 Chemical Generic Drug Reference Preparation Objection Application Form.
-
Brief description of new drug types, FIC/BIC/Me-too/Me-copy are silly and unclear
Time of Update: 2022-04-16
Different from foreign Me-too drugs, China's new Me-copy drugs are not optimized through high-throughput screening, starting from HITs, but with known active structures at the same target.
-
Exclusive writer: Blood products with scarce raw materials are first collected!
Time of Update: 2022-04-16
Judging from the list published in the report list, the intravenous injection of human immunoglobulin (pH4) and human immunoglobulin centralized collection involves nearly 30 companies, including Shanghai RAAS Blood Products, Hualan Bioengineering Chongqing, Shandong Taibang Biological products, Sichuan Yuanda Shuyang Pharmaceutical Co.
-
New regulations for the production and operation of medical devices have been introduced!
Time of Update: 2022-04-16
Strengthen the control of quality and safety risks, clarify the key points of production and operation supervision and inspection, and clarify the quality responsibilities and management requirements for the provision of transportation and storage services for medical device registrants, filers, and operating enterprises .
-
Hu Shanlian: Frontier Tracking of the Cost-effectiveness of New Crown Oral Drugs
Time of Update: 2022-04-16
The results of the phase III clinical trial were: the hospitalization and mortality rate of the treatment group was 7.
-
Heavy!
Time of Update: 2022-04-16
[2] "Chronic kidney disease kills 5 to 10 million people worldwide each year, and the lives of many patients are severely impacted by frequent dialysis treatments," said Associate Professor William Herrington, University of Oxford Population Health Clinical Scientist, Honorary Consultant in Nephrology, and EMPA-KIDNEY Co-Principal Investigator .
-
210 million yuan to introduce!
Time of Update: 2022-04-16
In China, a total of 4 long-acting Baiyao products have been approved for marketing, including Jinyouli from CSPC , Xinruibai from Qilu Pharmaceutical, Aido (19K for short) from Hengrui Medicine, and recombinant human granulocytes from Shandong New Era.
-
PHEXCOM VIP member unit IMCD is looking for sales managers!
Time of Update: 2022-04-16
Job Title: Sales ManagerSales Manager Responsibilities: 1.
Responsible for the promotion of pharmaceutical excipient products and create more business opportunities 2.
Develop and update sales forecasts in a timely manner, as well as the collection of accounts receivable 5.
Strong communication skills and business development skills 4.
-
The CDE article is a small auxiliary material, and the wrong use can also lead to life!
Time of Update: 2022-04-16
At present, China only proposes specific GMP requirements for excipient manufacturers to ensure the quality of excipients, but has not yet established a complete risk assessment system and guidelines for excipients, especially for MAH .
-
Eli Lilly, BMS, Roche, AstraZeneca lead the most anticipated new drug launch in 2022
Time of Update: 2022-04-16
donanemab [company] Eli Lilly [indication] Alzheimer's disease [2026 sales forecast] $6 billion In June last year, Biogen’s Aduhelm (aducanumab) targeting beta amyloid received accelerated approval from the FDA, and Evaluate had predicted that the drug’s peak sales in 2026 would be about $4.
-
Roche launched a HER2-ADC price war, which domestic companies may stand out
Time of Update: 2022-04-16
On January 21, 2020, T-DM1 was launched in China for the adjuvant treatment of patients with HER2-positive early breast cancer with residual invasive disease after receiving taxanes combined with trastuzumab-based neoadjuvant therapy It has become the first approved HER2-ADC drug in China, opening a new era of antibody-drug conjugate (ADC) therapy in China .
-
The State Food and Drug Administration has approved 12 new coronavirus antigen detection reagents
Time of Update: 2022-04-16
On March 15, after review by the State Food and Drug Administration, two new coronavirus antigen detection reagent products were approved .
As of March 16, the State Food and Drug Administration has approved 12 new coronavirus antigen detection reagent products .
-
Baiyunshan's cash flow has increased by 9 times, and the joint mining price of the eight provinces has been cut by more than 90%.
Time of Update: 2022-04-16
(National Medical Insurance Administration) Market tide Unnamed medicine faces the risk of termination of listing On March 21, the Shenzhen Stock Exchange issued a letter of concern about Shandong Weiming Biology.
-
Another domestic HPV vaccine is about to be approved!
Time of Update: 2022-04-15
[Pharmaceutical Network Industry News] Recently, the website of the Food and Drug Administration showed that the marketing application of the recombinant human papillomavirus bivalent (16/18 type) vaccine (yeast) of a subsidiary of Watson Bio (acceptance numbers: CXSS2000024, CXSS2000025, pre-filled The two dosage forms of syringe and vial) have entered the stage of "administrative approval" and are expected to be launched soon .
-
Since March, a number of pharmaceutical equipment companies have received the attention of securities companies' research reports
Time of Update: 2022-04-15
Since March, a number of pharmaceutical equipment companies have received the attention of research reports from securities companies, including Chutian Technology, Tofflon, and Chengyitong .
-
109 listed pharmaceutical companies plan to distribute over 26.3 billion yuan, and the total dividends of this company far exceed the annual net profit
Time of Update: 2022-04-15
According to Zhendong Pharmaceutical's announcement on March 31, the company's 2021 profit distribution plan is: to distribute cash dividends of 27 yuan (tax included) to all shareholders for every 10 shares, with a total cash dividend of more than 2.
-
With the continuous emergence of innovative achievements, pharmaceutical companies' innovative drug revenue growth rate is strong
Time of Update: 2022-04-15
It is worth mentioning that in the context of the continuous launch of innovative drugs, the growth rate of a large number of drug revenues is also very strong, which has brought benefits to many pharmaceutical companies .
-
The outbreak of anti-tumor drugs is imminent, and many pharmaceutical companies have several varieties under development
Time of Update: 2022-04-15
In the face of a considerable market blue ocean, in recent years, a large number of domestic and foreign pharmaceutical companies have been attacking the anti-tumor drug market, increasing investment in research and development, strengthening cooperation between companies, and enriching the company's product pipeline .
-
Another batch of pharmaceutical companies, layoffs!
Time of Update: 2022-04-15
Recently, another batch of pharmaceutical companies made layoff decisions: Biogen announced layoff-related matters to some employees in the United States; Dongpei Pharmaceuticals basically disbanded its sales team in China; Gilead plans to lay off 114 employees in Morris Plains, New Jersey.
-
For this variety of constipation treatment, many pharmaceutical companies have won bids to segment the market
Time of Update: 2022-04-15
On December 28, 2018, Watson Pharmaceuticals announced that the company's polyethylene glycol 4000 powder (specification: 10g) passed the consistency evaluation .
In the second batch of national centralized drug procurement, polyethylene glycol 4000 powder (10g) was won by 4 companies including Watson Pharmaceuticals .
